3-(dimethylamino)-1-(4-pyridinyl)-2-buten-1-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(dimethylamino)-1-(4-pyridinyl)-2-buten-1-one
• 英文别名: 1-(4-pyridyl)-2-(dimethylaminomethylene)ethanone；1-(pyridin-4-yl)-2-(dimethylaminomethylene)ethanone；(Z)-3-(dimethylamino)-1-pyridin-4-ylprop-2-en-1-one
• 化学式: C₁₀H₁₂N₂O
• 分子量: 176.218
• InChiKey: JZGHSXBVKSMAKH-YVMONPNESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(dimethylamino)-1-(4-pyridinyl)-2-buten-1-one 在 氢溴酸 、 potassium carbonate 作用下， 以 乙二醇甲醚 为溶剂， 反应 32.0h， 生成 4-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenol
  参考文献：
  名称：

  Preparation of substituted N-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitors

  摘要：

  The role of immunologically released mediators, such as histamine, leukotrienes, and platelet-activating factor, is well-established for asthma and other allergic disorders. Developing therapeutic agents which would block mediator release from mast cells and other relevant cell types would provide a rational approach to asthma therapy. Using human basophil as a screen, a series of 4-aryl-2-(phenylamino)pyrimidines was found which inhibited mediator release. These compounds were prepared by condensing acetyl heterocycles with dimethylformamide dimethyl acetal to form enaminones which are cyclized with aryl guanidines to give pyrimidines. After examining a large number of analogs, N-[3-(1H-imidazol-1-yl)phenyl]-4-(2-pyridinyl)-2-pyrimidinamine (1-27) was chosen for toxicological evaluation.

  DOI：

  10.1021/jm00071a002

文献信息

• 1,5-Diaryl substituted pyrazoles as p38 kinase inhibitors
  申请人：Pharmacia Corporation

  公开号：US06509361B1

  公开（公告）日：2003-01-21

  The present invention contemplates 1,5-diaryl-substituted pyrazole compounds that, inter alia, inhibit the activity of p38 MAP kinase. Also contemplated by the invention are processes for the preparation of the contemplated compounds and for the use of a contemplated compound in treating a mammalian host having a p38 kinase- or TNF-mediated disease.

  本发明涉及1,5-二芳基取代吡唑化合物，其中包括抑制p38 MAP激酶活性的化合物。本发明还涉及用于制备所述化合物以及用于治疗患有p38激酶或TNF介导疾病的哺乳动物宿主的预期化合物的方法。
• US6509361B1
  申请人：——

  公开号：US6509361B1

  公开（公告）日：2003-01-21
• Preparation of substituted N-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitors
  作者：Rolf Paul、William A. Hallett、John W. Hanifin、Marvin F. Reich、Bernard D. Johnson、Robert H. Lenhard、John P. Dusza、Suresh S. Kerwar、Yang I Lin

  DOI：10.1021/jm00071a002

  日期：1993.9

  The role of immunologically released mediators, such as histamine, leukotrienes, and platelet-activating factor, is well-established for asthma and other allergic disorders. Developing therapeutic agents which would block mediator release from mast cells and other relevant cell types would provide a rational approach to asthma therapy. Using human basophil as a screen, a series of 4-aryl-2-(phenylamino)pyrimidines was found which inhibited mediator release. These compounds were prepared by condensing acetyl heterocycles with dimethylformamide dimethyl acetal to form enaminones which are cyclized with aryl guanidines to give pyrimidines. After examining a large number of analogs, N-[3-(1H-imidazol-1-yl)phenyl]-4-(2-pyridinyl)-2-pyrimidinamine (1-27) was chosen for toxicological evaluation.